Arlington Capital Partners is seeking to sell Everest Clinical Research, a Toronto-based contract research organization, Axios Pro has learned from multiple sources.
Inside the room: Arlington recently interviewed sell-side advisors, and the business will be marketed on about $45 million of EBITDA.
